News for Array Biopharma Inc - Google Finance

Array Biopharma, Inc. (ARRY) Misses Q3 EPS by 4c; to Commence MEK162 ...

Mon, 06 May 2013 20:15:41 GMT

Array Biopharma, Inc. (ARRY) Misses Q3 EPS by 4c; to Commence MEK162 ...
StreetInsider.com (subscription) - May 6, 2013

Also today, Array announced the planned start of its first company-led Phase 3 trial with MEK162 in low-grade serous ovarian cancer.

ARRAY BIOPHARMA INC : Array Announces Global Phase 3 Trial Evaluating ... - 4-traders (press release)
Array reports decline in revenue, income - Boulder County Business Report

Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO ...

Wed, 15 May 2013 12:07:11 GMT

Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO ...
MarketWatch (press release) - May 15, 2013

BOULDER, Colo., May 15, 2013 /PRNewswire via COMTEX/ -- Array BioPharma Inc. (NASDAQ:ARRY) today announced presentations on its MEK inhibitors, MEK162 (licensed to Novartis) and selumetinib (licensed to AstraZeneca) at the 2013 American ...

Hot Stocks: SolarCity Corp (NASDAQ:SCTY), Array Biopharma Inc (NASDAQ ...

Wed, 08 May 2013 13:46:41 GMT

Hot Stocks: SolarCity Corp (NASDAQ:SCTY), Array Biopharma Inc (NASDAQ ...
SBWire (press release) - May 8, 2013

Array Biopharma Inc (NASDAQ:ARRY) shares fell 9.66% to $5.24. The company, on May 6, announced that it will initiate a global Phase 3 clinical trial in patients with recurrent low-grade serous ovarian cancer (LGSOC) during the summer of 2013.

Stock Losers: TravelCenters of America LLC, Array Biopharma Inc, Quicksilver ...

Wed, 08 May 2013 12:49:14 GMT

Stock Losers: TravelCenters of America LLC, Array Biopharma Inc, Quicksilver ...
SBWire (press release) - May 8, 2013

7 Small - Cap Stocks Look Ugly on Volatility : Ruckus Wireless , Synta ... - REM

Array BioPharma to Present at the Bank of America Merrill Lynch Healthcare ...

Wed, 08 May 2013 12:02:35 GMT

Array BioPharma to Present at the Bank of America Merrill Lynch Healthcare ...
MarketWatch (press release) - May 8, 2013

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.

Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?

Sun, 12 May 2013 22:13:24 GMT

Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
Seeking Alpha - May 12, 2013

Boulder, Colorado-based Array BioPharma Inc. (ARRY) is a $594M market cap biopharmaceutical company that discovers, develops and commercializes targeted small molecule drugs to treat cancers and inflammatory diseases.

Colorado stocks: ADA-ES gains 4%; Dow up 8 points (Video)

Sat, 25 May 2013 00:40:58 GMT

Colorado stocks: ADA-ES gains 4%; Dow up 8 points (Video)
Denver Business Journal - 4 hours ago

Array BioPharma Inc. (ABIO): up 3.36 percent, or 19 cents, to $5.85. • DigitalGlobe Inc. (DGI): up 2.06 percent, or 57 cents, to $28.27.

Array Biopharma Incorporated Price Target Increased to $6.50 by Analysts at ...

Fri, 10 May 2013 14:16:33 GMT

Array Biopharma Incorporated Price Target Increased to $6.50 by Analysts at ...
Mideast Time - May 10, 2013

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.

Array Biopharma Incorporated (ARRY) Updates FY13 Earnings Guidance

Mon, 06 May 2013 21:06:30 GMT

Array Biopharma Incorporated (ARRY) Updates FY13 Earnings Guidance
Zolmax - May 6, 2013

Should You Avoid ACADIA Pharmaceuticals Inc. (ACAD)?

Fri, 24 May 2013 17:27:57 GMT

Should You Avoid ACADIA Pharmaceuticals Inc. (ACAD)?
Insider Monkey (blog) - 12 hours ago

These stocks are Array Biopharma Inc (NASDAQ:ARRY), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Halozyme Therapeutics, Inc. (NASDAQ:HALO), and EXACT Sciences Corporation (NASDAQ:EXAS).